{
    "name": "methylphenidate transdermal",
    "comment": "Rx",
    "other_names": [
        "Daytrana"
    ],
    "classes": [
        "ADHD Agents",
        "Stimulants"
    ],
    "source": "https://reference.medscape.com/drug/daytrana-methylphenidate-transdermal-4000298",
    "pregnancy": {
        "common": [
            "Published studies and postmarketing reports on use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively",
                    "However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents",
                    "Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents"
                ]
            },
            {
                "type": "Clinical considerations ",
                "description": [
                    "CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion",
                    "No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers"
                ]
            },
            {
                "type": "Pregnancy exposure registry ",
                "description": [
                    "Monitors pregnancy outcomes in females exposed to ADHD medications",
                    "Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk",
            "There are no reports of adverse effects on breastfed infant and no effects on milk production; however, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown",
            "Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Abuse and dependence",
                    "description": [
                        "CNS psychiatrics#stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence",
                        "Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to methylphenidate or other components of product",
                "Coadministration with monoamine oxidase inhibitors (MAOIs) and within 14 days following discontinuing MAOIs",
                "Motor tics or with a family history or diagnosis of Tourette syndrome",
                "Glaucoma",
                "Patients with marked anxiety, tension, and agitation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy",
                "May cause an increase in blood pressure (BP) and heart rate (HR); monitor for hypertension and tachycardia",
                "Prolonged and painful erections, sometimes requiring surgical intervention, reported with methylphenidate products, including another formulation of methylphenidate hydrochloride extended-release tablets, in both pediatric and adult patients",
                "Priapism was not reported with drug initiation but developed during treatment, often after an increase in dose and during a period of drug withdrawal (drug holidays or during discontinuation); if such reaction occurs, seek immediate medical attention",
                "CNS psychiatrics#stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms are usually intermittent and generally improve after dose reduction or discontinuing treatment; monitor for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients",
                "Closely monitor growth (weight and height) in pediatric patients treated with psychiatrics#stimulants; patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted",
                "Stimulants may lower the convulsive threshold in patients with a history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures; if seizures occur, discontinue drug",
                "Difficulties with accommodation and blurry vision reported ",
                "Periodic complete blood cell count, differential, and platelet counts are advised during prolonged therapy",
                "Use may result in a persistent loss of skin pigmentation at and around the application site; monitor for signs of skin depigmentation and advise patients to immediately inform healthcare provider if changes in skin pigmentation occur; discontinue use in patients with chemical leukoderma",
                "Use may lead to contact sensitization; discontinue if contact sensitization is suspected",
                "Avoid exposing site to direct external heat sources, such as hair dryers, heating pads, electric blankets, heated water beds, etc., while wearing the patch"
            ],
            "specific": [
                {
                    "type": "Psychiatric adverse reactions ",
                    "description": [
                        "CNS psychiatrics#stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder",
                        "CNS psychiatrics#stimulants may also induce a manic or mixed episode in patients",
                        "Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression)",
                        "CNS psychiatrics#stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur"
                    ]
                },
                {
                    "type": "Serious cardiovascular reactions",
                    "description": [
                        "Sudden death, stroke, and myocardial infarction report in adults",
                        "Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems",
                        "Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems",
                        "Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "MAOIs",
                        "Contraindicated",
                        "Do administer during or within 14 days of discontinuing MAOI treatment",
                        "Coadministration of MAOIs with CNS psychiatrics#stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure",
                        "Antihypertensive drugs",
                        "Monitor BP and adjust dose of antihypertensive drugs accordingly",
                        "Methylphenidate may decrease effectiveness of antihypertensive drugs",
                        "Risperidone",
                        "Monitor for signs of extrapyramidal symptoms (EPS)",
                        "Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS",
                        "Vasopressor agents",
                        "Use with caution",
                        "Vasopressors may exacerbate the effects of methylphenidate on BP",
                        "Anticoagulants, antidepressants, and selective serotonin reuptake inhibitors",
                        "Decrease adjustments of these drugs may be required when coadministered methylphenidate; monitor plasma drug concentrations (or, in the case of coumarin, coagulation times), when initiating or discontinuing methylphenidate",
                        "Studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), and some tricyclic drugs (eg, imipramine, clomipramine, desipramine) and selective serotonin reuptake inhibitors"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "methylphenidate transdermal and isocarboxazid both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "methylphenidate transdermal and phenelzine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rasagiline",
            "description": {
                "common": "methylphenidate transdermal and rasagiline both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "safinamide",
            "description": {
                "common": "methylphenidate transdermal and safinamide both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "methylphenidate transdermal and selegiline both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "methylphenidate transdermal and selegiline transdermal both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "methylphenidate transdermal and tranylcypromine both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "methylphenidate transdermal decreases effects of acebutolol by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of acetazolamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "methylphenidate transdermal decreases effects of amiloride by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of amitriptyline by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of amoxapine by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azilsartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of azilsartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of benazepril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of candesartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of cannabidiol by  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of captopril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of carbamazepine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of cenobamate by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "methylphenidate transdermal decreases effects of chlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "methylphenidate transdermal decreases effects of chlorthalidone by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of citalopram by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of clobazam by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of clomipramine by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of clonazepam by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of clorazepate by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "methylphenidate transdermal and conivaptan both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of desipramine by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desmopressin",
            "description": {
                "common": "methylphenidate transdermal and desmopressin both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of diazepam by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam buccal",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of diazepam buccal by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of diazepam intranasal by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of divalproex sodium by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of doxepin by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of enalapril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of eprosartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of escitalopram by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of eslicarbazepine acetate by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "methylphenidate transdermal decreases effects of esmolol by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of ethosuximide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of ethotoin by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of ezogabine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felbamate",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of felbamate by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of fenfluramine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of fluoxetine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of fluvoxamine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of fosinopril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of fosphenytoin by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "methylphenidate transdermal decreases effects of hydrochlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of imipramine by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "methylphenidate transdermal decreases effects of indapamide by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of irbesartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of lacosamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of lamotrigine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of lisinopril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of lorazepam by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of losartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of methsuximide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methylphenidate transdermal decreases effects of methyclothiazide by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "methylphenidate transdermal decreases effects of metolazone by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of midazolam by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of midazolam intranasal by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of moexipril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of nortriptyline by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of olmesartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of oxcarbazepine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of paroxetine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perampanel",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of perampanel by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of perindopril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of phenobarbital by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of phenytoin by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of pregabalin by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of primidone by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "methylphenidate transdermal decreases effects of propranolol by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of protriptyline by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of quinapril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of ramipril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of risperidone by  unspecified interaction mechanism. Use Caution/Monitor. When coadministered with methylphenidate, changes in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS). Monitor for signs of EPS."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rufinamide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of rufinamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of sacubitril/valsartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of sertraline by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "methylphenidate transdermal decreases effects of sotalol by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "methylphenidate transdermal decreases effects of spironolactone by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of stiripentol by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of telmisartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terlipressin",
            "description": {
                "common": "methylphenidate transdermal and terlipressin both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiagabine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of tiagabine by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "methylphenidate transdermal and tolvaptan both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of topiramate by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "methylphenidate transdermal decreases effects of trandolapril by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "methylphenidate transdermal decreases effects of triamterene by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of trimipramine by  decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of valproic acid by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "methylphenidate transdermal decreases effects of valsartan by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vasopressin",
            "description": {
                "common": "methylphenidate transdermal and vasopressin both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vigabatrin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of vigabatrin by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of warfarin by  decreasing metabolism. Modify Therapy/Monitor Closely. Decreasing the dose of these drugs may be required when given coadministered with methylphenidate. Consider monitoring plasma drug concentrations (or INR with coumadin), when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zonisamide",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of zonisamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Decreased appetite",
            "percent": "25.5"
        },
        {
            "name": "Headache",
            "percent": "15.3"
        },
        {
            "name": "Insomnia",
            "percent": "13.3"
        },
        {
            "name": "Nausea",
            "percent": "12.2"
        },
        {
            "name": "Vomiting",
            "percent": "10.2"
        },
        {
            "name": "Decreased appetite",
            "percent": "25.5"
        },
        {
            "name": "Headache",
            "percent": "12.4"
        },
        {
            "name": "Irritability",
            "percent": "11"
        },
        {
            "name": "Weight decreased",
            "percent": "9.2"
        },
        {
            "name": "Irritability",
            "percent": "7.1"
        },
        {
            "name": "Tic",
            "percent": "7.1"
        },
        {
            "name": "Abdominal pain",
            "percent": "7.1"
        },
        {
            "name": "Affect lability",
            "percent": "6.1"
        },
        {
            "name": "Anorexia",
            "percent": "5.1"
        },
        {
            "name": "Tachycardia",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "9.7"
        },
        {
            "name": "Insomnia",
            "percent": "6.2"
        },
        {
            "name": "Weight decreased",
            "percent": "5.5"
        },
        {
            "name": "Dizziness",
            "percent": "5.5"
        },
        {
            "name": "Abdominal pain",
            "percent": "4.8"
        },
        {
            "name": "Anorexia",
            "percent": "4.8"
        },
        {
            "name": "Vomiting",
            "percent": "3.4"
        },
        {
            "name": "Tachycardia",
            "percent": "0.7"
        }
    ]
}